Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has received a consensus recommendation of “Hold” from the ten research firms that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $18.00.

A number of analysts have weighed in on the stock. Piper Jaffray Companies set a $20.00 target price on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, July 29th. BidaskClub lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. Zacks Investment Research lowered shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 16th. BMO Capital Markets restated a “hold” rating and issued a $16.00 target price on shares of Amphastar Pharmaceuticals in a research report on Monday, July 31st. Finally, ValuEngine lowered shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday.

ILLEGAL ACTIVITY NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/08/25/amphastar-pharmaceuticals-inc-amph-receives-18-00-average-target-price-from-analysts.html.

In other news, Director Richard K. Prins sold 5,000 shares of Amphastar Pharmaceuticals stock in a transaction on Monday, August 14th. The shares were sold at an average price of $14.80, for a total transaction of $74,000.00. Following the transaction, the director now owns 33,844 shares in the company, valued at $500,891.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jason B. Shandell sold 11,482 shares of Amphastar Pharmaceuticals stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $16.92, for a total transaction of $194,275.44. Following the transaction, the director now owns 241,342 shares in the company, valued at approximately $4,083,506.64. The disclosure for this sale can be found here. In the last quarter, insiders have sold 51,482 shares of company stock worth $842,225. 11.10% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the company. Alps Advisors Inc. raised its position in shares of Amphastar Pharmaceuticals by 0.3% in the second quarter. Alps Advisors Inc. now owns 39,250 shares of the company’s stock worth $701,000 after buying an additional 101 shares during the period. Louisiana State Employees Retirement System raised its position in shares of Amphastar Pharmaceuticals by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the company’s stock worth $212,000 after buying an additional 200 shares during the period. Arizona State Retirement System raised its position in Amphastar Pharmaceuticals by 1.1% in the first quarter. Arizona State Retirement System now owns 18,700 shares of the company’s stock valued at $271,000 after buying an additional 200 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in Amphastar Pharmaceuticals by 2.8% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,430 shares of the company’s stock valued at $151,000 after buying an additional 230 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Amphastar Pharmaceuticals by 1.1% in the second quarter. The Manufacturers Life Insurance Company now owns 28,701 shares of the company’s stock valued at $512,000 after buying an additional 312 shares during the last quarter. Institutional investors own 43.83% of the company’s stock.

Amphastar Pharmaceuticals (AMPH) traded up 0.97% during mid-day trading on Tuesday, reaching $15.58. The company had a trading volume of 110,168 shares. The company’s 50 day moving average is $16.60 and its 200 day moving average is $15.87. The stock has a market capitalization of $719.72 million, a price-to-earnings ratio of 202.34 and a beta of 1.65. Amphastar Pharmaceuticals has a 52-week low of $12.05 and a 52-week high of $21.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, August 9th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05. Amphastar Pharmaceuticals had a net margin of 1.61% and a return on equity of 2.42%. The firm had revenue of $65.20 million for the quarter, compared to analyst estimates of $63.40 million. During the same quarter last year, the business posted $0.23 earnings per share. The company’s quarterly revenue was down 4.1% on a year-over-year basis. Equities analysts predict that Amphastar Pharmaceuticals will post $0.27 earnings per share for the current year.

Amphastar Pharmaceuticals declared that its Board of Directors has approved a share repurchase program on Wednesday, August 9th that allows the company to buyback $20.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Stock Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.